Reportlinker Adds HIV-AIDS Therapeutics - Pipeline Assessment and Market Forecasts to 2017
NEW YORK, May 24, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
HIV-AIDS Therapeutics - Pipeline Assessment and Market Forecasts to 2017
HIV-AIDS Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData has released its new report, "HIV-AIDS Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV-AIDS therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global HIV/AIDS therapeutics sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimated the HIV/AIDS therapeutics market to be worth $12.3 billion in 2010. GlobalData expects the HIV/AIDS therapeutics market to grow at a compound annual growth rate (CAGR) of 5% from $12.3 billion in 2010 to approximately $17.3 billion in 2017. The introduction of multi-class combination products has contributed to the growth of the market.
Scope
The report provides information on the key drivers and challenges of the HIV/AIDS therapeutics market. Its scope includes -
- Annualized global HIV/AIDS therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as nucleoside reverse transcriptase inhibitors (NRTI), integrase inhibitors, protease inhibitors, fusion inhibitors, nonnucleoside reverse transcriptase inhibitors (NNRTI), anti-neoplastic agents, interleukin inhibitors, chemokine (C-C motif) receptor 5 (CCR5) antagonists and enzyme inhibitors.
- Analysis of the current and future competition in the global HIV/AIDS therapeutics market. Key market players covered are GlaxoSmithKline and Gilead Sciences.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the HIV/AIDS therapeutics market.
- Analysis of key recent licensing and partnership agreements in HIV/AIDS therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HIV/AIDS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global HIV/AIDS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global HIV/AIDS therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 HIV/AIDS: Introduction 6
2.1 Overview 6
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 9
2.4 Symptoms 11
2.5 Diagnosis 12
2.6 Treatment and Management Pattern 13
2.7 GlobalData Pipeline Report Guidance 13
3 HIV-AIDS Therapeutics: Market Characterization 14
3.1 HIV-AIDS Therapeutics Market Size - Global 14
3.2 HIV-AIDS Therapeutics Market Forecast and CAGR - Global 15
3.3 HIV-AIDS Therapeutics Market Size – The US 16
3.4 HIV-AIDS Therapeutics Market Forecast – The US 17
3.5 HIV-AIDS Therapeutics Market Size - France 18
3.6 HIV-AIDS Therapeutics Market Forecast - France 19
3.7 HIV-AIDS Therapeutics Market Size - Germany 20
3.8 HIV-AIDS Therapeutics Market Forecast - Germany 21
3.9 HIV-AIDS Therapeutics Market Size - Italy 22
3.10 HIV-AIDS Therapeutics Market Forecast - Italy 23
3.11 HIV-AIDS Therapeutics Market Size - Spain 24
3.12 HIV-AIDS Therapeutics Market Forecast - Spain 25
3.13 HIV-AIDS Therapeutics Market Size – The UK 26
3.14 HIV-AIDS Therapeutics Market Forecast - The UK 27
3.15 HIV-AIDS Therapeutics Market Size - Japan 28
3.16 HIV-AIDS Therapeutics Market Forecast - Japan 29
3.17 Drivers and Barriers for the HIV-AIDS Therapeutics Market 30
3.17.1 Drivers of the HIV-AIDS Therapeutics Market 30
3.17.2 Barriers for the HIV-AIDS Therapeutics Market 31
3.18 Opportunity and Unmet Need Analysis 32
3.19 Key Takeaway 32
4 HIV-AIDS Therapeutics: Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Major Marketed Product Profiles in the HIV-AIDS Therapeutics Market 34
4.3.1 Atripla (efavirenz, emtricitabine, and tenofovir) 34
4.3.2 Truvada (emtricitabine/tenofovir disoproxil fumarate) 35
4.3.3 Kaletra (lopinavir/ritonavir) 36
4.3.4 Reyataz (atazanavir sulfate) 36
4.3.5 Fuzeon (enfuvirtide) 37
4.3.6 Isentress (raltegravir) 38
4.3.7 Sustiva (efavirenz) 38
4.4 Key Takeaway 40
5 HIV-AIDS Therapeutics: Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.3 HIV-AIDS Therapeutics Pipeline – Pipeline by Clinical Phases of Development 41
5.3.1 HIV-AIDS Therapeutics – Phase III Clinical Pipeline 42
5.3.2 HIV-AIDS Therapeutics – Phase II Clinical Pipeline 42
5.3.3 HIV-AIDS Therapeutics – Phase I Clinical Pipeline 44
5.3.4 HIV-AIDS – Preclinical Pipeline 45
5.3.5 HIV-AIDS – Discovery Clinical Pipeline 46
5.4 HIV-AIDS Therapeutics – Pipeline by Mechanism of Action 47
5.5 Technology Trends Analytic Framework 48
5.6 HIV-AIDS Therapeutics – Most Promising Drugs under Clinical Development 50
5.7 Most Promising Drugs Profile 51
5.7.1 TMC278 (rilpivirine hydrochloride) 51
5.7.2 Quad (elvitegravir/GS-9350/emtricitabine/tenofovir) 52
5.7.3 Elvitegravir 53
5.7.4 GSK1349572 54
5.8 Key Takeaway 54
6 HIV-AIDS Therapeutics: Clinical Trials Mapping 55
6.1 Clinical Trials by Region/Country (The US, EU5 & Japan) 55
6.2 Clinical Trials by Phase of Clinical Development 56
6.3 Clinical Trials by Trial Status 57
6.4 Prominent Sponsors 58
6.5 Top Ten Companies Participating in Therapeutics Clinical Trials 60
7 HIV-AIDS Therapeutics: Strategic Assessment 61
7.1 Key Events impacting the Future Market 61
7.2 Future Market Competition Scenario 62
8 HIV-AIDS Therapeutics: Future Players 64
8.1 Introduction 64
8.2 GlaxoSmithKline plc 64
8.2.1 Overview 64
8.2.2 Financial Overview 64
8.2.3 Business Overview 65
8.2.4 Deals, Alliances and Partnerships 66
8.3 Gilead Sciences, Inc. 70
8.3.1 Overview 70
8.3.2 Business Description 70
8.3.3 Deals, Alliances and Partnerships 71
8.4 Other Companies in HIV-AIDS Therapeutics Market 72
9 HIV-AIDS Therapeutics: Licencing & Partnership Deals 76
10 HIV-AIDS Therapeutics Market: Appendix 80
10.1 Market Definitions 80
10.2 Abbreviations 80
10.3 Methodology 81
10.3.1 Coverage 81
10.3.2 Secondary Research 81
10.3.3 Forecasting 82
10.3.4 Primary Research 85
10.3.5 Expert Panel Validation 85
10.4 Contact Us 85
10.5 Disclaimer 85
10.6 Bibliography 86
1.1 List of Tables
Table 1: HIV-AIDS Therapeutics Market, Global, WHO Immunological Classification for Established HIV Infection 8
Table 2: HIV-AIDS Therapeutics Market, Global, Regional Statistics, 2009 8
Table 3: HIV-AIDS Therapeutics Market, Global, Revenue ($m), 2005–2010 14
Table 4: HIV-AIDS Therapeutics Market, Global, Forecast ($m), 2010–2017 15
Table 5: HIV-AIDS Therapeutics Market, The US, Revenue ($m), 2005–2010 16
Table 6: HIV-AIDS Therapeutics Market, The US, Forecast ($m), 2010–2017 17
Table 7: HIV-AIDS Therapeutics Market, France, Revenue ($m), 2005–2010 18
Table 8: HIV-AIDS Therapeutics Market, France, Forecast ($m), 2010–2017 19
Table 9: HIV-AIDS Therapeutics Market, Germany, Revenue ($m), 2005–2010 20
Table 10: HIV-AIDS Therapeutics Market, Germany, Forecast ($m), 2010–2017 21
Table 11: HIV-AIDS Therapeutics Market, Italy, Revenue ($m), 2005–2010 22
Table 12: HIV-AIDS Therapeutics Market, Italy, Forecast ($m), 2010–2017 23
Table 13: HIV-AIDS Therapeutics Market, Spain, Revenue ($m), 2005–2010 24
Table 14: HIV-AIDS Therapeutics Market, Spain, Forecast ($m), 2010–2017 25
Table 15: HIV-AIDS Therapeutics Market, The UK, Revenue ($m), 2005–2010 26
Table 16: HIV-AIDS Therapeutics Market, The UK, Forecast ($m), 2010–2017 27
Table 17: HIV-AIDS Therapeutics Market, Japan, Revenue ($m), 2005–2010 28
Table 18: HIV-AIDS Therapeutics Market, Japan, Forecast ($m), 2010–2017 29
Table 19: Major Marketed Products in the HIV-AIDS Therapeutics Market, 2010 39
Table 20: HIV-AIDS Therapeutics, Phase III Pipeline, 2010 42
Table 21: HIV-AIDS Therapeutics, Phase II Pipeline, 2010 42
Table 22: HIV-AIDS Therapeutics, Phase I Pipeline, 2010 44
Table 23: HIV-AIDS Therapeutics, Preclinical Pipeline, 2010 45
Table 24: HIV-AIDS Therapeutics, Discovery Clinical Pipeline, 2010 46
Table 25: HIV-AIDS Therapeutics Market, Most Promising Drugs Under Clinical Development, 2010 50
Table 26: HIV-AIDS Therapeutics Market, Global, Clinical Trials, 2010 55
Table 27: HIV-AIDS Therapeutics, Global, Clinical Trials by Phase, 2010 56
Table 28: HIV-AIDS Therapeutics, Global, Clinical Trials by Status of Development, 2010 57
Table 29: HIV-AIDS Therapeutics, Global, Prominent Sponsors, 2010 59
Table 30: HIV-AIDS Therapeutics Market, Global, Top Ten Companies by Phase, 2010 60
Table 31: GlaxoSmithKline – Deals, Alliances and Partnerships 66
Table 32: Gilead Sciences-Deals, 2010-11 71
Table 33: HIV-AIDS Therapeutics Market - Future Players, 2010 72
Table 34: HIV-AIDS Therapeutics Market, Global, Deals, 2010 76
1.2 List of Figures
Figure 1: HIV-AIDS Therapeutics Market, Global, HIV Group M Subtypes 7
Figure 2: HIV-AIDS Therapeutics Market, Global, Number of People suffering from HIV/AIDS, 2009 9
Figure 3: HIV-AIDS Therapeutics Market, Global, HIV-AIDS Transmission Methods 10
Figure 4: HIV-AIDS Therapeutics Market, Global, HIV-AIDS Symptoms 12
Figure 5: HIV-AIDS Therapeutics Market, Global, Revenue ($m), 2005–2010 14
Figure 6: HIV-AIDS Therapeutics Market, Global, Forecast ($m), 2010–2017 15
Figure 7: HIV-AIDS Therapeutics Market, The US, Revenue ($m), 2005–2010 16
Figure 8: HIV-AIDS Therapeutics Market, The US, Forecast ($m), 2010–2017 17
Figure 9: HIV-AIDS Therapeutics Market, France, Revenue ($m), 2005–2010 18
Figure 10: HIV-AIDS Therapeutics Market, France, Forecast ($m), 2010–2017 19
Figure 11: HIV-AIDS Therapeutics Market, Germany, Revenue ($m), 2005–2010 20
Figure 12: HIV-AIDS Therapeutics Market, Germany, Forecast ($m), 2010–2017 21
Figure 13: HIV-AIDS Therapeutics Market, Italy, Revenue ($m), 2005–2010 22
Figure 14: HIV-AIDS Therapeutics Market, Italy, Forecast ($m), 2010–2017 23
Figure 15: HIV-AIDS Therapeutics Market, Spain, Revenue ($m), 2005–2010 24
Figure 16: HIV-AIDS Therapeutics Market, Spain, Forecast ($m), 2010–2017 25
Figure 17: HIV-AIDS Therapeutics Market, The UK, Revenue ($m), 2005–2010 26
Figure 18: HIV-AIDS Therapeutics Market, The UK, Forecast ($m), 2010–2017 27
Figure 19: HIV-AIDS Therapeutics Market, Japan, Revenue ($m), 2005–2010 28
Figure 20: HIV-AIDS Therapeutics Market, Japan, Forecast ($m), 2010–2017 29
Figure 21: Opportunity and Unmet Need in the HIV-AIDS Market, 2010 32
Figure 22: Strategic Competitor Assessment of the Major Marketed Products in HIV/AIDS, 2010 33
Figure 23: HIV-AIDS Therapeutics, Pipeline by Phases of Development (%), 2010 41
Figure 24: HIV-AIDS Therapeutics Market, Pipeline by Mechanism of Action (%), 2010 47
Figure 25: Technology Trends Analytic Framework of the HIV-AIDS Therapeutics Pipeline, Drugs, 2010 48
Figure 26: Technology Trends Analytic Framework of the HIV-AIDS Therapeutics Pipeline, Description, 2010 49
Figure 27: HIV-AIDS Therapeutics Market, Global, Clinical Trials by Country, 2010 55
Figure 28: HIV-AIDS Therapeutics, Global, Clinical Trials by Phase, 2010 56
Figure 29: HIV-AIDS Therapeutics, Global, Clinical Trials by Status of Development, 2010 57
Figure 30: HIV-AIDS Therapeutics, Global, Overall Sponsors, 2010 58
Figure 31: HIV-AIDS Therapeutics, Global, Prominent Sponsors, 2010 59
Figure 32: HIV-AIDS Therapeutics Market, Global, Top Ten Companies by Phase, 2010 60
Figure 33: HIV-AIDS Therapeutics Market, Global, Key Events impacting the Future Market, 2010 61
Figure 34: HIV-AIDS Therapeutics Market, Implications for Future Market Competition, 2010 62
Figure 35: HIV-AIDS Therapeutics, Clinical Pipeline by Company, 2010 64
Figure 36: GlobalData Market Forecasting Model 84
Companies MentionedGlaxoSmithKline plc
Gilead Sciences, Inc.
To order this report:
Pathology Industry: HIV-AIDS Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article